Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL

Gaoxiang Wang, Meijuan Huang, Lijun Jiang, Xiaoying Zhang, Z.m. Wang, Qiuxia Yu, Dengju Li, Yang Yang, Yang CaoCancer 2025 · DOI

TL;DR

When the first round of CAR T-cell therapy fails for B-cell lymphoma, a second infusion (CTI2) might seem like a logical next step, but this study suggests we should be extremely cautious. While CTI2 offers a better short-term response at 30 days, it does not improve long-term survival and carries a significantly higher risk of fatal infections compared to other salvage treatments.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (R/R B-NHL). However, the "miracle cure" doesn't work for everyone: roughly 10–30% of patients don't respond to the first infusion (CTI1), and 30–60% of those who do eventually relapse.

The clinical community faces a desperate question: What is the best salvage strategy after CTI1 fails? Some clinicians opt for a second CAR T-cell infusion (CTI2), while others turn to traditional chemotherapy, radiotherapy, or newer targeted drugs. Until now, there hasn't been a systematic comparison of these post-failure paths. This paper evaluates whether doubling down on CAR T-cells is actually effective or if it simply adds toxicity without extending life.

Methods

The researchers conducted a retrospective analysis of 61 R/R B-NHL patients at Tongji Hospital in China who failed an initial "cocktail" CAR T-cell therapy (targeting both CD19 and CD22).

The cohort was split into two groups:

  1. CTI2 Group (n=27): Patients who received a second CAR T-cell infusion.
  2. Non-CTI2 Group (n=34): Patients who received other salvage therapies, including radiotherapy, conventional chemotherapy, or molecularly targeted drugs (like Polatuzumab vedotin).

The team used Kaplan–Meier survival analysis and Cox proportional hazards models to identify risk factors. They also tracked CAR T-cell expansion in the blood using droplet digital PCR (ddPCR) to see if the "fitness" of the second batch of cells correlated with patient outcomes.

Datasets

The study utilized a clinical dataset of 61 adult patients treated between January 2017 and May 2022. All patients had previously failed a CD19/22 cocktail CAR T-cell therapy. This represents one of the largest domestic studies specifically focusing on management strategies after CTI1 failure in B-NHL.

Key Insights and Ideas

  • The "Transient Response" Trap: CTI2 achieved a significantly higher Overall Response Rate (ORR) at the 30-day mark compared to other therapies (8/27 vs. 2/34). However, this "win" was short-lived; the response didn't translate into long-term survival.
  • The High Cost of Immunosuppression: The most striking finding was the mortality rate. Infection-related deaths were significantly higher in the CTI2 group (13/22) compared to the non-CTI2 group (4/19). The researchers hypothesize that the cumulative "double hit" of lymphodepletion and CAR T-cell activity severely weakens the immune system beyond its breaking point.
  • Tumor Biology Trumps Treatment Choice: Multivariate analysis revealed that the only independent risk factor for survival was the status of the tumor at disease onset (specifically, "bulky disease" or masses ≥7.5 cm). Surprisingly, the type of salvage therapy chosen (CTI2 vs. non-CTI2) was not an independent predictor of survival.
  • A Glimmer of Hope in Targeted Therapy: Although the sample size was tiny (n=3), patients treated with a combination of Polatuzumab vedotin, bendamustine, and rituximab (PV+BR) showed promising results, suggesting that molecularly targeted drugs might be a safer and more effective pivot than a second CAR T-cell dose.

Key Results

  • Short-term Response: CTI2 had a better 30-day ORR (P = 0.014).
  • Long-term Survival: The non-CTI2 group had significantly better Event-Free Survival (EFS, P = 0.007) and Overall Survival (OS, P = 0.048).
  • Median Follow-up: 6.7 months for non-CTI2 vs. 4.7 months for CTI2.
  • Infection Risk: Grade 3+ infections were more common in the CTI2 group (18/27 vs. 12/34, P = 0.021).
  • Overall Prognosis: Regardless of the treatment, the prognosis for patients failing CTI1 remains extremely poor, with a median OS of only 6.3 months for the entire cohort.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: As a retrospective study, there is inherent selection bias in which patients were assigned to which treatment.
  • Sample Size: While large for this specific sub-population, 61 patients is still a small cohort, particularly when breaking down the "non-CTI2" group into specific drug regimens.
  • Focus on Adults: The results may not apply to pediatric patients or those with B-cell acute lymphoblastic leukemia (B-ALL), where CTI2 might behave differently.

Future Directions: The paper calls for large-scale prospective trials and the development of entirely new strategies—such as bispecific antibodies or novel CAR constructs with higher efficiency and lower toxicity—rather than simply repeating failed approaches.

Summary updated

Abstract

Chimeric antigen receptor (CAR) T-cell infusion (CTI) therapy has emerged as a breakthrough therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL), but a substantial number of patients still suffer treatment failure. Data on disease history, subsequent salvage therapies, and outcomes of patients who face treatment failure after the first CTI (CTI1) have not been reported in detail or systematically studied. Here, a retrospective analysis was performed on a total of 61 R/R B-NHL patients in whom salvage therapies were adopted after CTI1 treatment failure, with their clinical characteristics, subsequent management and outcomes described in detail. The results suggested that second-time CTI (CTI2) used as salvage therapy after failure of CTI1 could achieve a better transient overall response rate (ORR) than other salvage treatments (non-CTI2) in only a minority of patients (8/27 vs. 2/34, P=0.014). Nevertheless, the non-CTI2 group showed better event-free survival (EFS) (P = 0.007) and overall survival (OS) (P = 0.048) than the CTI2 group, with a median follow-up of 6.7 months vs. 4.7 months. In addition, univariate and multivariate analyses showed that only the status of the tumor at disease onset was an independent risk factor for survival; salvage therapy after CTI1 treatment failure was not. The adverse effects of CTI2 treatment were generally similar to those of non-CTI2 treatment, but the infection-related mortality was considerably higher. In conclusion, the prognosis of patients who fail CTI1 therapy is very poor regardless of the subsequent salvage therapies, and clinicians should be cautious about adopting CTI2 treatment after failure of treatment with the CD19/22 cocktail CTI1 in R/R B-NHL. Large-scale prospective studies are warranted, and new strategies are urgently needed to prevent treatment failure and improve the survival of B-cell lymphoma patients in future.
BibTeX
@inproceedings{wang2025be,
  author = {Gaoxiang Wang and Meijuan Huang and Lijun Jiang and Xiaoying Zhang and Z.M. Wang and Qiuxia Yu and Dengju Li and Yang Yang and Xin Yang and Yang Cao},
  title = {{Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1007/s00262-025-04001-7},
}
Figure